
1. Malar J. 2016 Sep 20;15:479. doi: 10.1186/s12936-016-1535-8.

Failure of dihydroartemisinin plus piperaquine treatment of falciparum malaria by
under-dosing in an overweight patient.

Roseau JB(1)(2), Pradines B(3)(4)(5), Paleiron N(2)(6), Vedy S(2), Madamet
M(7)(8)(9), Simon F(10)(11), Javelle E(12).

Author information: 
(1)Service de Pneumologie, Hôpital d'Instruction des Armées Laveran, Marseille,
France.
(2)Groupe Médico-chirurgical Bouffard, Djibouti, Republic of Djibouti.
(3)Unité de Parasitologie et d'Entomologie, Département des Maladies
Infectieuses, Institut de Recherche Biomédicale des Armées, Marseille, France.
bruno.pradines@gmail.com.
(4)Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, UM 
63, CNRS 7278, IRD 198, Inserm 1095, Aix Marseille Université, Marseille, France.
bruno.pradines@gmail.com.
(5)Centre National de Référence du Paludisme, Marseille, France.
bruno.pradines@gmail.com.
(6)Service de Pneumologie, Hôpital d'Instruction des Armées Clermont-Tonnerre,
Brest, France.
(7)Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, UM 
63, CNRS 7278, IRD 198, Inserm 1095, Aix Marseille Université, Marseille, France.
(8)Centre National de Référence du Paludisme, Marseille, France.
(9)Equipe Résidente de Recherche en Infectiologie Tropicale, Institut de
Recherche Biomédicale des Armées, Hôpital d'Instruction des Armées, Marseille,
France.
(10)Service de pathologie infectieuse et tropicale, Hôpital d'Instruction des
Armées Laveran, Marseille, France.
(11)Ecole du Val de Grâce, Paris, France.
(12)Service de pathologie infectieuse et tropicale, Hôpital d'Instruction des
Armées Laveran, Marseille, France. emilie.javelle@gmail.com.

BACKGROUND: Artemisinin-based combination therapy (ACT) introduced in the
mid-1990s has been recommended since 2005 by the World Health Organization as
first-line treatment against Plasmodium falciparum in all endemic countries. In
2010, the combination dihydroartemisinin-piperaquine (DP) was recommended for the
treatment of uncomplicated P. falciparum malaria. DP is one of the first-line
treatments used by the French army since 2013.
CASE PRESENTATION: A case of P. falciparum clinical failure with DP at day 20 was
described in a 104 kg French soldier deployed in Djibouti. He was admitted to
hospital for supervision of oral treatment with DP [40 mg dihydroartemisinin
(DHA) plus 320 mg piperaquine tetraphosphate (PPQ)]. This corresponded to a
cumulative dose of 4.6 mg/kg DHA and 37 mg/kg PPQ in the present patient, which
is far below the WHO recommended ranges. No mutation was found in the propeller
domain of the Kelch 13 (k13) gene, which is associated with artemisinin
resistance in Southeast Asia. Pfmdr1 N86, 184F, S1034 and N1042 polymorphisms and
haplotype 72-76 CVIET for the pfcrt gene were found in the present case. There
was no evidence of resistance to DP.
CONCLUSION: This case confirms the risk of therapeutic failure with
dihydroartemisinin-piperaquine by under-dosing in patients weighing more than
100 kg. This therapeutic failure with DP by under-dosing highlighted the
importance of appropriate dosing guidelines and the need of research data
(efficacy, pharmacokinetics and pharmacodynamics) in over-weight patient group.

DOI: 10.1186/s12936-016-1535-8 
PMCID: PMC5028982
PMID: 27646822  [Indexed for MEDLINE]

